CLINICAL_TRIALS
research
· 2026-04-07
Clinical Trial Update: Dose Optimization of Caffeine for HIE [Phase 1]
Summary
Phase 1 trial update exploring dose optimization of caffeine citrate for Hypoxic-Ischemic Encephalopathy. Recruitment is ongoing.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of North Carolina, Chapel Hill | Conditions: Hypoxic-Ischemic Encephalopathy | Phase 1 | Status: RECRUITING